Pill Packets

Pharmaceuticals 'not doing enough' to develop new antibiotics

By: Information Daily Staff Writer
Published: Tuesday, November 19, 2013 - 17:04 GMT Jump to Comments

Pharmaceutical companies are not doing enough to develop new antibiotics following an increase in antibiotic-resistant infections worldwide, said Dr Jason Clark, Chief Technology Officer of Novolytics.

Speaking exclusively to the Information Daily at Global Health 2013: Rise of the Resistance, Dr Clark explained how Novolytics aims to exploit the therapeutic potential offered by bacteriophages (“phages”) in a way which is commercially viable and attractive to its investors.

A bacteriophage is a virus that infects bacteria and is seen as a possible future treatment against strains of antibiotic-resistant infections. It is understood that phages kill one quarter of the bacteria on the planet every day.

Dr Clark said: “Bacteriophages are everywhere. They're on your skin, in your food, phages are in your stomach, you probably have more phages in your body than you do bacteria and they're completely inert in humans and other mammals so they're very safe”.

Dr Clark explained precisely how his company is treating antibiotic resistant infections: “At our company we use bacteriophages to treat antibiotic resistant infections, bacteria phages are viruses which only infect bacteria, what they do is infect and kill bacteria such as MRSA and E coli”.

Right now the company are in the stages of research just before Phase 1 clinical trials. All three phases of the clinical trials would take almost ten years to be completed, even though phases 1 and 2 are relatively quick.

“There’s quite a large body of literature suggesting that they are very safe and that they do work, the issue is that they have not been purified in a manner that’s consistent with western regulatory standards.

"They have not been taken through the full clinical trials process and that’s what we are trying to do", said Dr Clark.

Comments

Latest

Can health and social care delivered through smart technology and the internet really save the NHS as the NHS…

The Shadow Business Secretary has come out strongly in support of regional devolution and the mood in Birmingham…

Attribute exchange can be a way of saving money for both the private and public purse and a way of reducing friction…

My time at school was spent staring at blackboards and scrawling in notebooks, but things are changing……

Organisations like the Manufacturing Advisory Service have a key role in ensuring suppliers are aware of the opportunities…

For some companies, working with government and doing business in devolved city regions will mean big challenges:…

On the surface the 5YFV looks positive for general practice, but on closer inspection it signals a significant…

Enabling people to transact with public services online will bring substantial savings, hence the call for services…

Do you do digital? Take the test

The Information Daily is collaborating with Socitm to research organisations' commitment to and capability for a digital future.

Take the test

View Results

If you have already taken the test, you may view the latest detailed results by entering your email address below


Headline results so far: Results from 113 users

Corporate commitment: 46%
0%
100%
50%
Digital capability: 52%
0%
100%
50%

The DISCOVER project is a European collaboration between Birmingham City University, the Open University and Aristotle…

Ben Gowland CEO Nene CCG and Joe Tibbetts publisher of Health Care Innovation Daily discuss Simon Stevens' five…

Local authorities are facing unprecedented challenges over the medium term, including those relating to austerity…

Former cabinet minister Hazel Blears MP will join the InformationDaily.TV AnswerTime® live studio debate…